Rigel Pharmaceuticals (RIGL) Finished Goods (2018 - 2025)
Rigel Pharmaceuticals has reported Finished Goods over the past 8 years, most recently at $1.8 million for Q3 2025.
- For Q3 2025, Finished Goods fell 69.37% year-over-year to $1.8 million; the TTM value through Sep 2025 reached $1.8 million, down 69.37%, while the annual FY2024 figure was $5.0 million, 232.49% up from the prior year.
- Finished Goods for Q3 2025 was $1.8 million at Rigel Pharmaceuticals, down from $2.7 million in the prior quarter.
- Over five years, Finished Goods peaked at $5.8 million in Q3 2024 and troughed at $962000.0 in Q1 2021.
- A 5-year average of $2.3 million and a median of $1.6 million in 2023 define the central range for Finished Goods.
- Biggest five-year swings in Finished Goods: skyrocketed 232.49% in 2024 and later tumbled 69.37% in 2025.
- Year by year, Finished Goods stood at $1.3 million in 2021, then soared by 45.12% to $1.9 million in 2022, then fell by 20.8% to $1.5 million in 2023, then skyrocketed by 232.49% to $5.0 million in 2024, then crashed by 64.38% to $1.8 million in 2025.
- Business Quant data shows Finished Goods for RIGL at $1.8 million in Q3 2025, $2.7 million in Q2 2025, and $3.8 million in Q1 2025.